Medifast stock: Steamboat fund buys 82,700 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP purchased Medifast Inc. shares in four transactions. On November 18, 2026, they bought 8,630 and 256 shares, respectively, at an average $12.1613 per share; on November 19, they bought 82,700 and 2,450 shares, respectively, at an average $12.0464. Director Kiai Parsa may be deemed to have a pecuniary interest in the shares and disclaims beneficial ownership except to that extent. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F3, F5 | 82,700 | $12.0464 | $996K |
| Purchase | Common Stock F2, F3, F5 | 2,450 | $12.0464 | $30K |
| Purchase | Common Stock F1, F3, F4 | 8,630 | $12.1613 | $105K |
| Purchase | Common Stock F2, F3, F4 | 256 | $12.1613 | $3K |
Footnotes (5)
- F1. Ownership of Steamboat Capital Partners Master Fund, LP (Master) which has delegated investment discretion to Steamboat Capital Partners, LLC (IA).
- F2. Ownership of Steamboat Capital Partners II, LP (II).
- F3. Steamboat Capital Partners GP, LLC (GP) is general partner of, and entitled to receive a performance allocation from, each of Master and II. Parsa Kiai ("Kiai") is the Managing Member of GP and IA. Accordingly, Kiai may be deemed to have a pecuniary interest in the shares owned by Master and II. Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein.
- F4. This is an average price. Actual prices paid for the shares purchased on 11/18/26 and reported on this line range from $12.06 to $12.20. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This is an average price. Actual prices paid for the shares purchased on 11/19/26 and reported on this line range from $11.855 to $12.15. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
investment discretion financial
pecuniary interest financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the reported MED purchase prices?
AI-generated analysis. How Rhea-AI works. Not financial advice.